Entresto Sprinkle (Sacubitril/Valsartan) Patent Expiration, LOE Window & CMS Spending
Entresto Sprinkle (Sacubitril/Valsartan) by Novartis: FDA Orange Book core substance LOE 2027-05-27 (last listed 2037-02-02), 16 AB generics, $145K 2024 CMS Part D & Medicaid spend.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Novartis |
| FDA Application & Pathway | N218591 (NDA) |
| Exclusivity / Cliff Horizon | Long-Dated Protection (2036+) |
| Core Active-Ingredient LOE Date | 2027-05-27 |
| Last Listed Patent or Exclusivity Date | 2037-02-02 |
| Orange Book Patents (*PED Extensions) | 3 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 16 |
| 2024 CMS Total Public Spend | $145K |
| 2024 Medicare Part D Spend | $145K |
| 2024 Medicaid Spend | $0 |
| Reported Wholesale Price Change (CA SB 17) | 0 statutory filings in 2023 to 2026 panel |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Novartis across sibling Meru public-data platforms.